This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

Bispecific antibody engineering and therapeutics - WHITEPAPER


Download the exclusive whitepaper

Through the last two decades, a phenomenal evolution of bispecific antibodies has developed in front of our eyes, with this “zoo” of bispecificity being populated by many different species: there are small molecules made exclusively of the antigenbinding sites of two antibodies; molecules with an Immunoglobulin G (IgG) structure; and, large complex molecules composed of different antigen-binding moieties, often combined with dimerization modules.

This whitepaper looks at:

  • Latest industry developments, discoveries and investment in bispecific antibodies

  • Emerging bispecific technologies/modes of action

  • Current challenges facing (pre-)clinical development

  • Discovery strategies

  • Bispecific target discovery, identification and validation strategies

To download the exclusive whitepaper simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.


ABOUT THE AUTHOR: Dr Catarina Carrao gained a PhD in Biochemistry from Northeastern Ohio Medical and Pharmacy University and an M.Phil in Biochemistry at the University of Beira Interior. She has worked as a researcher at Max F. Perutz Laboratories, Yale Cardiovascular Center at Yale University School of Medicine, and the Center Cardiovascular Research (CCR) at
Charité Medical University.

Have any questions about the whitepaper or interested in sponsoring a future whitepaper? Email

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.